
Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the interleukin-6 receptor, indicated for the